XOMA Ltd. – Product Pipeline Review – H2 2011
Global Markets Direct
November 28, 2011 123 Pages - SKU: GMD6692849
|
|
XOMA Ltd. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “XOMA Ltd. - Product Pipeline Review - H2 2011” provides data on the XOMA Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, XOMA Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from XOMA Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - XOMA Ltd. - Brief XOMA Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of XOMA Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of XOMA Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the XOMA Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate XOMA Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of XOMA Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the XOMA Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with XOMA Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of XOMA Ltd. and identify potential opportunities in those areas.
|
- XOMA Ltd. Snapshot
- XOMA Ltd. Overview
- Key Information
- Key Facts
- XOMA Ltd. - Research and Development Overview
- Key Therapeutic Areas
- XOMA Ltd. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Pipeline Products - Combination Treatment Modalities
- XOMA Ltd. - Pipeline Products Glance
- XOMA Ltd. Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- XOMA Ltd.-Early Stage Pipeline Products
- Pre-Clinical Products/Combination Treatment Modalities
- XOMA Ltd. - Drug Profiles
- F10 Antibody Program
- Multiple Preclinical Programs
- XOMA 052
- XOMA 052 + Sitagliptin
- XOMA 3AB
- XOMA Ltd. - Pipeline Analysis
- XOMA Ltd. - Pipeline Products by Therapeutic Class
- XOMA Ltd. - Pipeline Products By Target
- XOMA Ltd. - Pipeline Products by Route of Administration
- XOMA Ltd. - Pipeline Products by Molecule Type
- XOMA Ltd. - Recent Pipeline Updates
- XOMA Ltd. - Dormant Projects
- XOMA Ltd. - Discontinued Pipeline Products
- Discontinued Pipeline Product Profiles
- MLN2201
- XOMA Ltd. - Company Statement
- XOMA Ltd. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Mar 22, 2011: XOMA Announces Top Line Results From Phase IIb Study Of XOMA 052
- Jan 11, 2011: XOMA Presents XOMA 3AB Data At National Biodefense Meeting
- Nov 09, 2011: XOMA Expands Gevokizumab Program
- Jun 08, 2011: XOMA Announces Phase IIa Six-Month Top Line Trial Results Of XOMA 052
- Jan 06, 2011: XOMA Reports Interim Three Month Data From Ongoing Six Month Phase IIa Trial Of Type 2 Diabetes Drug Candidate
- May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
- Financial Deals Landscape
- XOMA Ltd., Deals Summary
- XOMA Ltd., Pharmaceuticals & Healthcare, Deal Details
- Partnerships
- XOMA Enters Into Research Agreement With KAKETSUKEN
- XOMA Enters Into Agreement With Chiron
- XOMA Enters Into Co-Development Agreement With Diversa
- Licensing Agreements
- XOMA Expands BCE Licensing Agreement With Crucell
- XOMA Enters Into Licensing Agreement With Zephyr
- XOMA Enters Into Licensing Agreement With Diversa
- Equity Offering
- XOMA Completes Public Offering Of Common Stock For $6.7 Million
- XOMA Completes Public Offering Of $12 Million
- XOMA Completes Private Placement Of $10 Million
- Debt Offering
- XOMA Completes Public Offering Of Notes For $12 Million
- XOMA Completes Private Placement Of 6.5% Convertible Senior Notes For $60 Million
- Asset Transactions
- XOMA Sells Royalty Rights Of Cimzia
- Genentech Acquires Royalty Interest Of LUCENTIS From XOMA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- XOMA Ltd. - Pipeline by Therapy Area and Indication, H2 2011
- XOMA Ltd. - Pipeline by Stage of Development, H2 2011
- XOMA Ltd. - Monotherapy Products in Pipeline, H2 2011
- XOMA Ltd. - Combination Treatment Modalities in Pipeline, H2 2011
- XOMA Ltd. - Phase II, H2 2011
- XOMA Ltd. - Phase I, H2 2011
- XOMA Ltd. - Pipeline By Therapeutic Class, H2 2011
- XOMA Ltd. - Pipeline By Target, H2 2011
- XOMA Ltd. - Pipeline By Route of Administration, H2 2011
- XOMA Ltd. - Pipeline By Molecule Type, H2 2011
- XOMA Ltd. - Recent Pipeline Updates, H2 2011
- XOMA Ltd. - Dormant Developmental Projects, 2010
- XOMA Ltd. - Discontinued Pipeline Products, 2010
- XOMA Ltd., Subsidiaries
- XOMA Ltd., Deals Summary
- XOMA Enters Into Research Agreement With KAKETSUKEN
- Xoma Enters Into Agreement With Arana Therapeutics
- XOMA Enters Into Research Agreement With Zymeworks
- Takeda Pharmaceutical Expands Collaboration With XOMA
- XOMA Amends Co-Development Agreement With Novartis Vaccines and Diagnostics
- XOMA Expands Collaboration With Takeda Pharmaceutical
- XOMA Enters Into Co-Development Agreement With Texas A&M University
- Takeda Pharmaceutical Expands Agreement With XOMA
- XOMA Expands Research Agreement With Schering-Plough
- Takeda Pharmaceutical Enters Into An Agreement With XOMA
- XOMA And Attenuon Enter Into Co-Development Agreement To Humanize Novel Anti-Cancer Antibody
- Schering-Plough Enters Into An Agreement With XOMA
- Lexicon Enters Into Collaboration Agreement With XOMA
- XOMA Enters Into Collaboration Agreement With Aphton
- XOMA Enters Into Agreement With Chiron
- XOMA Enters Into Co-Development Agreement With Diversa
- XOMA Expands BCE Licensing Agreement With Crucell
- XOMA Enters Into Licensing Agreement With Les Laboratoires Servier For XOMA 052
- Wacker Biotech Enters Into Licensing Agreement With XOMA
- XOMA Enters Into Licensing Agreement With Pfizer
- XOMA Enters Into Licensing Agreement With Affimed Therapeutics
- Affimed Therapeutics Enters Into Licensing Agreement With XOMA
- XOMA Enters Into Licensing Agreement With AVEO Pharmaceuticals
- Crucell Enters Into Licensing Agreement With XOMA
- Affitech Enters Into License Agreement With XOMA
- XOMA Enters Into Licensing Agreement With Affitech
- XOMA Enters Into Licensing Agreement With Wyeth
- XOMA Enters Into Licensing Agreement With Merck & Co
- XOMA Enters Into Licensing Agreement With Zephyr
- XOMA Enters Into Licensing Agreement With Diversa
- XOMA Completes Public Offering Of Common Stock For $6.7 Million
- XOMA Completes Public Offering Of $30 Million
- Xoma Completes First Tranche Of Private Placement Of $14.2 Million With Azimuth Opportunity
- XOMA Completes Underwritten Public Offering Of $21 Million
- XOMA Completes Private Placement Of $14 Million
- XOMA Completes Public Offering Of $12 Million
- XOMA Completes Private Placement Of $10 Million
- XOMA Completes Public Offering Of Notes For $12 Million
- XOMA Completes Private Placement Of 6.5% Convertible Senior Notes For $60 Million
- XOMA Sells Royalty Rights Of Cimzia
- Genentech Acquires Royalty Interest Of LUCENTIS From XOMA
- List of Figures
- XOMA Ltd. - Pipeline by Therapy Area and Indication, H2 2011
- XOMA Ltd. - Pipeline by Stage of Development, H2 2011
- XOMA Ltd. - Monotherapy Products in Pipeline, H2 2011
- XOMA Ltd. - Combination Treatment Modalities in Pipeline, H2 2011
- XOMA Ltd. - Pipeline By Therapeutic Class, H2 2011
- XOMA Ltd. - Pipeline By Target, H2 2011
- XOMA Ltd. - Pipeline By Route of Administration, H2 2011
- XOMA Ltd. - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
